Osmotica Pharmaceuticals (NASDAQ:OSMT) Announces Quarterly Earnings Results, Misses Expectations By $0.52 EPS

Osmotica Pharmaceuticals (NASDAQ:OSMT) announced its quarterly earnings results on Wednesday. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.52), MarketWatch Earnings reports. Osmotica Pharmaceuticals had a negative return on equity of 42.38% and a negative net margin of 142.64%. The business had revenue of $59.91 million during the quarter, compared to the consensus estimate of $53.88 million.

Shares of OSMT traded down $0.47 during trading hours on Thursday, reaching $3.28. 17,507 shares of the company traded hands, compared to its average volume of 236,683. The firm has a market cap of $237.51 million and a price-to-earnings ratio of -6.69. Osmotica Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $7.97. The company has a current ratio of 2.13, a quick ratio of 1.78 and a debt-to-equity ratio of 1.92. The stock’s fifty day moving average price is $5.45 and its 200 day moving average price is $5.22.

Several equities research analysts recently weighed in on the stock. BidaskClub cut shares of Osmotica Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 4th. SunTrust Banks initiated coverage on shares of Osmotica Pharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $8.00 price objective on the stock. SVB Leerink initiated coverage on shares of Osmotica Pharmaceuticals in a research report on Friday, March 6th. They set an “outperform” rating and a $10.00 price objective on the stock. ValuEngine upgraded shares of Osmotica Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Finally, Zacks Investment Research cut shares of Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 21st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Osmotica Pharmaceuticals has an average rating of “Buy” and an average target price of $9.75.

In other Osmotica Pharmaceuticals news, Director Sriram Venkataraman acquired 1,250,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average cost of $5.00 per share, with a total value of $6,250,000.00. Following the completion of the purchase, the director now directly owns 22,485,297 shares in the company, valued at $112,426,485. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.70% of the stock is currently owned by insiders.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Recommended Story: When is a capital gain realized?

Earnings History for Osmotica Pharmaceuticals (NASDAQ:OSMT)

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.